Inhibition of BRAF (V600E) leads to a feedback to reactivate the EGFR signaling; therefore, a combination of the BRAF inhibitor encorafenib and cetuximab improves treatment efficacy in CRC.48,49 We deduced that targeting EGFR–ERK activation (cetuximab) and ILF3–SGOC (NCT-503) might have a synergistic effect. This evidence concerns the gene BRAF and colorectal carcinoma.